What's New at Isto

Isto Biologics Sponsors Preceptorship on Autologous Therapy in Lower Extremity Orthopedics and Neurologic Procedures

Isto Biologics’ Medical Education team recently supported a biologics Hospital-Based Observation Preceptorship led by Dr. Edgardo Rodriguez, DPM. Course attendees were educated on autologous therapy using the Magellan® Autologous Concentration System in lower extremity orthopedics and neurologic procedures.

The program offered multiple days of hands-on learning of autologous therapy applications using the Magellan technology. Under the direction of Dr. Rodriguez, Director of the Chicago Foot & Ankle Deformity Correction Center, the program was comprised of a day-long cadaver skills lab and didactics session, a full day in a clinical setting, and one full day in a surgical setting.  Isto’s Medical Education team was on hand to review the Magellan system and the advantages of Isto Biologics products—including InQu, a cell-friendly bone graft extender & substitute.

Dr. Rodriguez specializes in treating complex lower limb conditions such as congenital and acquired post-traumatic angular deformities, and focuses on disorders such as clubfoot, post-polio, tibia and fibular hemimelia.  He is the Co-Founder and Medical Chairman of the Chicago Lower Extremity Surgical Foundation, Founder and Chair of the Chicago Ilizarov Lower Limb Reconstructive Society, and Director of the Adult & Pediatric Ilizarov Lower Limb Traveling Fellowship.  Dr. Rodriguez is an active member of the Department of Surgery at Presence Saint Joseph Hospital and Saint Anthony Hospital in Chicago, as well as Methodist Hospital in Merrillville, Indiana.  He has trained in the United States, Italy and Russia to learn the application of the Ilizarov technique, and has performed over 1,000 cases with external fixation.

The Magellan is an autologous concentration system with flexibility to process both bone marrow and whole blood, providing high concentrations of platelets and progenitor cells in low final output volumes.

No Comments Yet

Let us know what you think